THOMAS H. BECK leads the New York IP group, and focuses on complex chemical and pharmaceutical litigation matters. In 2012, Mr. Beck’s team won a 2-week jury trial for Sunovion in Hatch-Waxman litigation against Mylan concerning the asthma drug Xopenex® (levalbuterol), winning lost profits, reasonable royalty and a finding of willful infringement. The National Law Journal listed that verdict in the top 100 jury verdicts for 2012, and it was also in the top 20 IP jury awards for 2012.
The 2014 IAM 1000 ranking states: "Thomas Beck takes a lead role on the Sunovion files and impresses with his 'easygoing manner in tough New York court battles'. 'He is a strategic thinker who makes brilliant presentations.'" Mr. Beck is recognized as a Litigation Star in Benchmark Litigation for 2014 and 2015, and is a “Life Sciences Star” in LMG Life Sciences for 2012, 2013 and 2014. In Who’s Who Legal in 2010, he was described as “world class.” Mr. Beck has been ranked since 2005 in Chambers USA: “extremely well-versed in patent law ... tenacious litigation style ... studious and organized approach”... ability to “dig very deep into the science” of patent matters (2008) and “a great thinker who gets into the details and works hard to come up with winning strategies” (2009). He was ranked in the 2015 The Best Lawyers in America, since 2004 in the Practical Law Company Handbooks, and was profiled in the November 2003 IP Law & Business article, “Hooked on Drugs” (p. 36-44) concerning the Bristol v. RPRlitigation.
Sunovion v. Mylan/Dey (D.Del. 2/10/2012) — lead counsel for Plaintiff Sunovion in winning 2-week jury trial, including $18 million in lost profits and reasonable royalty, plus a jury finding of willful infringement. Previously defeated Defendants’ motion for summary judgment to preclude Sunovion’s lost profits claims (12/7/2011). The National Law Journal listed that verdict in the top 100 jury verdicts for 2012, and it was also in the top 20 IP jury awards for 2012.
Bristol-Myers Squibb Company v. Rhone-Poulenc Rorer, Inc., 2002 WL 59429 (SDNY 2002) — lead counsel in case finding inequitable conduct by patent owner RPR, after bifurcated trial on inequitable conduct issues. Affirmed by the Federal Circuit at 326 F.3d 1226 (2003). Substantial attorney fees awarded. Obtained ruling of crime-fraud to pierce the attorney client privilege, and ruling of limited French privilege applicable to in-house attorneys including general counsel.